Upstream Bio, Inc. (UPB): Total Liabilities
$14.00M
As of 2025-12-31
$10.21M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.00M | +18.0% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $11.87M | +26.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $9.39M | n/a | 2025-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $14.00M | +18.0% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $422.65M | -4.3% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $968.0K | +8.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.52M | -19.0% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $2.27M | -34.4% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
Compare UPB, RNAC, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗